Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 4
2007 4
2008 4
2009 2
2010 4
2011 8
2012 1
2013 10
2014 7
2015 5
2016 4
2017 4
2018 4
2019 1
2020 3
2021 3
2022 2
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. da Silva EM, et al. Cochrane Database Syst Rev. 2016 Feb 5;2(2):CD008185. doi: 10.1002/14651858.CD008185.pub4. Cochrane Database Syst Rev. 2016. PMID: 26845288 Free PMC article. Review.
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of participants at the end of the study and they were related to a smaller reduction in urine glycosaminoglycan levels. ...
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of p …
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. da Silva EM, et al. Cochrane Database Syst Rev. 2014 Jan 8;(1):CD008185. doi: 10.1002/14651858.CD008185.pub3. Cochrane Database Syst Rev. 2014. PMID: 24399699 Updated. Review.
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of patients at the end of the study and they were related to a smaller reduction in urine glycosaminoglycan levels. ...
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of p …
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. da Silva EM, et al. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008185. doi: 10.1002/14651858.CD008185.pub2. Cochrane Database Syst Rev. 2011. PMID: 22071845 Updated. Review.
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of patients at the end of the study and they were related to a smaller reduction in urine glycosaminoglycan levels. ...
Idursulfase was generally well tolerated, but infusion reactions did occur. Idursulfase antibodies were detected in 31.7% of p …
Idursulfase: I2S, iduronato-2-sulfatase.
[No authors listed] [No authors listed] Drugs R D. 2006;7(4):254-8. doi: 10.2165/00126839-200607040-00005. Drugs R D. 2006. PMID: 16784250 Review. No abstract available.
IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.
Kim J, Park MR, Kim DS, Lee JO, Maeng SH, Cho SY, Han Y, Ahn K, Jin DK. Kim J, et al. Allergy. 2013 Jun;68(6):796-802. doi: 10.1111/all.12155. Epub 2013 Apr 29. Allergy. 2013. PMID: 23621439
Western blotting was performed to confirm the reaction between idursulfase and specific IgE. RESULTS: Three patients (8.8%) showed anaphylaxis by infusion of idursulfase. ...SPT with idursulfase demonstrated positive results in all patients with anaphylaxis. …
Western blotting was performed to confirm the reaction between idursulfase and specific IgE. RESULTS: Three patients (8.8%) showed an …
Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
Whiteman DA, Kimura A. Whiteman DA, et al. Drug Des Devel Ther. 2017 Aug 23;11:2467-2480. doi: 10.2147/DDDT.S139601. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28860717 Free PMC article. Review.
Preclinical studies utilizing the intravenous route of administration provided valuable insights that informed the design of the subsequent clinical studies. The pivotal Phase II/III clinical trial of intravenous idursulfase (Elaprase(); Shire, Lexington, MA, USA) demonstr …
Preclinical studies utilizing the intravenous route of administration provided valuable insights that informed the design of the subsequent …
Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II.
Muenzer J, Burton BK, Harmatz P, Gutiérrez-Solana LG, Ruiz-Garcia M, Jones SA, Guffon N, Inbar-Feigenberg M, Bratkovic D, Hale M, Wu Y, Yee KS, Whiteman DAH, Alexanderian D; SHP609-302 study group. Muenzer J, et al. Mol Genet Metab. 2022 Sep-Oct;137(1-2):92-103. doi: 10.1016/j.ymgme.2022.07.016. Epub 2022 Aug 2. Mol Genet Metab. 2022. PMID: 35961250 Free article. Clinical Trial.
A formulation of idursulfase for intrathecal administration (idursulfase-IT) is under investigation for the treatment of neuronopathic MPS II. ...Participants were also enrolled in this extension from a linked non-randomized sub-study of children younger than 3 year …
A formulation of idursulfase for intrathecal administration (idursulfase-IT) is under investigation for the treatment of neuro …
Long-term open-label phase I/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II.
Muenzer J, Vijayaraghavan S, Stein M, Kearney S, Wu Y, Alexanderian D. Muenzer J, et al. Genet Med. 2022 Jul;24(7):1437-1448. doi: 10.1016/j.gim.2022.04.002. Epub 2022 May 20. Genet Med. 2022. PMID: 35588317 Free article. Clinical Trial.
PURPOSE: Intrathecal (IT) idursulfase-IT for the treatment of cognitive impairment is being investigated in pediatric patients with neuronopathic mucopolysaccharidosis II (MPS II) in addition to intravenous idursulfase. ...RESULTS: In total, 15 participants received …
PURPOSE: Intrathecal (IT) idursulfase-IT for the treatment of cognitive impairment is being investigated in pediatric patients with n …
A phase I/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II.
Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, Solanki GA, Mascelli MA, Pan L, Wang N, Sciarappa K, Barbier AJ. Muenzer J, et al. Genet Med. 2016 Jan;18(1):73-81. doi: 10.1038/gim.2015.36. Epub 2015 Apr 2. Genet Med. 2016. PMID: 25834948 Free article. Clinical Trial.
We examined the safety of idursulfase formulated for intrathecal administration (idursulfase-IT) via intrathecal drug delivery device (IDDD). ...METHODS: Sixteen cognitively impaired males with mucopolysaccharidosis II who were previously treated with weekly i.v. …
We examined the safety of idursulfase formulated for intrathecal administration (idursulfase-IT) via intrathecal drug delivery …
61 results